AU2023228915A1 - QUINOLINE cGAS ANTAGONIST COMPOUNDS - Google Patents

QUINOLINE cGAS ANTAGONIST COMPOUNDS Download PDF

Info

Publication number
AU2023228915A1
AU2023228915A1 AU2023228915A AU2023228915A AU2023228915A1 AU 2023228915 A1 AU2023228915 A1 AU 2023228915A1 AU 2023228915 A AU2023228915 A AU 2023228915A AU 2023228915 A AU2023228915 A AU 2023228915A AU 2023228915 A1 AU2023228915 A1 AU 2023228915A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
ring
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023228915A
Other languages
English (en)
Inventor
Chuo Chen
Zhijian Chen
Jian Qiu
Heping Shi
Lijun Sun
Huiling TAN
Matt Tschantz
Qi Wei
Youtong Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Immunesensor Therapeutics Inc
Original Assignee
University of Texas System
University of Texas at Austin
Immunesensor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Immunesensor Therapeutics Inc filed Critical University of Texas System
Publication of AU2023228915A1 publication Critical patent/AU2023228915A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023228915A 2022-03-02 2023-03-02 QUINOLINE cGAS ANTAGONIST COMPOUNDS Pending AU2023228915A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315968P 2022-03-02 2022-03-02
US63/315,968 2022-03-02
US202363478467P 2023-01-04 2023-01-04
US63/478,467 2023-01-04
PCT/US2023/063623 WO2023168367A1 (en) 2022-03-02 2023-03-02 QUINOLINE cGAS ANTAGONIST COMPOUNDS

Publications (1)

Publication Number Publication Date
AU2023228915A1 true AU2023228915A1 (en) 2024-09-19

Family

ID=85781707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023228915A Pending AU2023228915A1 (en) 2022-03-02 2023-03-02 QUINOLINE cGAS ANTAGONIST COMPOUNDS

Country Status (11)

Country Link
US (3) US12281078B2 (https=)
EP (1) EP4486734A1 (https=)
JP (1) JP2025507820A (https=)
KR (1) KR20250004639A (https=)
CN (1) CN119137112A (https=)
AU (1) AU2023228915A1 (https=)
CA (1) CA3253386A1 (https=)
IL (1) IL315346A (https=)
MX (1) MX2024010674A (https=)
TW (1) TW202342021A (https=)
WO (1) WO2023168367A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
CN119137112A (zh) 2022-03-02 2024-12-13 免疫传感器治疗股份有限公司 喹啉cGAS拮抗剂化合物
WO2026050765A1 (en) 2024-08-30 2026-03-05 Immunesensor Therapeutics, Inc. Solid forms and salts of a quinoline cgas antagonist compound
WO2026057087A1 (zh) * 2024-09-14 2026-03-19 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) * 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
AU2008303602A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
JP2019501904A (ja) * 2015-12-14 2019-01-24 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ Ｄｎａメチルトランスフェラーゼの阻害剤としての２，４，６，７−四置換キノリン化合物
CN109111426B (zh) 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
IL302338B2 (en) 2017-09-08 2024-10-01 Univ Leland Stanford Junior Enpp1 inhibitors and their use for the treatment of cancer
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
US12064433B2 (en) 2018-07-27 2024-08-20 Arcus Biosciences, Inc. Pyridone A2R antagonists
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020142735A1 (en) 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN115209883B (zh) 2020-01-20 2025-05-20 新月生物科学 新型细胞代谢调节化合物及其用途
JP2023532998A (ja) 2020-07-06 2023-08-01 クレセンタ バイオサイエンシズ 新規細胞代謝調節化合物およびそのウイルス性疾患の治療のための使用
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
CN119137112A (zh) 2022-03-02 2024-12-13 免疫传感器治疗股份有限公司 喹啉cGAS拮抗剂化合物

Also Published As

Publication number Publication date
US20240002346A1 (en) 2024-01-04
US20230357158A1 (en) 2023-11-09
TW202342021A (zh) 2023-11-01
CN119137112A (zh) 2024-12-13
KR20250004639A (ko) 2025-01-08
CA3253386A1 (en) 2023-09-07
JP2025507820A (ja) 2025-03-21
US12091387B2 (en) 2024-09-17
MX2024010674A (es) 2024-11-08
EP4486734A1 (en) 2025-01-08
IL315346A (en) 2024-11-01
US12281078B2 (en) 2025-04-22
US20260042737A1 (en) 2026-02-12
WO2023168367A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
WO2023168367A1 (en) QUINOLINE cGAS ANTAGONIST COMPOUNDS
KR102516038B1 (ko) cGAS 길항제 화합물
AU2017345736B2 (en) TYK2 inhibitors and uses thereof
AU2021336977A1 (en) Quinoline cGAS antagonist compounds
CN105073736B (zh) 作为呼吸道合胞病毒抗病毒剂的喹喔啉酮和二氢喹喔啉酮
CA2930414A1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
AU2010343055A1 (en) Heteroaryl compounds and uses thereof
WO2013067302A1 (en) Method of treatment
US20240279224A1 (en) Quinolines and azaquinolines as inhibitors of cd38
US20240309005A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
US20240368177A1 (en) 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5
EP4562016A2 (en) Cdk2 inhibitors and methods of using the same
US10278973B2 (en) Hydroxyl purine compounds and use thereof
JPWO2023168367A5 (https=)
HK40120448A (zh) 喹啉cgas拮抗剂化合物
CN107614501A (zh) 羟基嘌呤类化合物及其应用
CA3109195A1 (en) Transglutaminase 2 (tg2) inhibitors